Dose reduction of glucocorticoids in systemic lupus erythematosus

FHS
June 13, 2024
5:09 pm

Glucocorticoids are a mainstay of treatment for systemic lupus erythematosus (SLE). But due to long-term adverse effects, dose reduction is becoming a crucial part of treat-to-target management goals.

Gilead agrees to pay $247M to settle HIV drug case that alleged competition blocking

Details of a proposed HIV settlement with Gilead are now public, but its fate hinges on a federal judge’s OK next month. KPH Healthcare Services,

August 12, 2023

Health AI startups: How long do they take to hit $10 million in sales

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in

October 24, 2024

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression – Psychedelic Alpha

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already

February 3, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.